2018
Cell-Based Immunotherapy of Gliomas
Everson R, Antonios J, Liau L. Cell-Based Immunotherapy of Gliomas. Progress In Neurological Surgery 2018, 32: 90-100. PMID: 29990977, DOI: 10.1159/000469683.Peer-Reviewed Original ResearchConceptsCellular immunotherapyImmune cellsDendritic cell (DC)-based vaccinesTreatment of malignant gliomasCellular immunotherapy approachesAntitumor immune cellsAntitumor responseAdoptive transferImmunotherapy approachesActive immunotherapyLive immune cellsMalignant gliomasEffector capabilitiesPassive immunotherapyImmunotherapyImmune responseEx vivoImmune systemGlioma cellsCell typesPatientsGliomaCellsNeoplasms
2014
IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA
Antonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA. Neuro-Oncology 2014, 16: v110-v110. PMCID: PMC4218227, DOI: 10.1093/neuonc/nou258.1.Peer-Reviewed Original ResearchProgrammed death-1Tumor-infiltrating lymphocytesPost-implant dayCombination groupPD-1Tumor microenvironmentLymph nodesTreatment groupsEffective anti-tumor immune responseFACS analysisAnti-tumor immune activityAnti-tumor immune responseIncreased tumor-infiltrating lymphocytesAnti-PD1 mAbNegative costimulatory moleculesPD-1 mAbDendritic cell vaccinesAnti-tumor responsesImmunocompetent C57BL/6 miceTumor-bearing hemisphereDecreased tumor volumeGL261 glioma cellsCombined treatment groupAntitumor responseDeath-1